Ovid Therapeutics Inc.
Business
Ovid Therapeutics is a biopharmaceutical company developing small molecule medicines for brain disorders characterized by neuronal hyperexcitation, including epilepsy, psychosis, schizophrenia, and mood disorders. The company's pipeline includes OV329, a next-generation GABA-aminotransferase inhibitor for drug-resistant focal onset seizures and developmental epileptic encephalopathies, and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator for psychosis and schizophrenia. Ovid builds its portfolio through in-licensing and clinical development of compounds with differentiated mechanisms of action targeting fundamental neuronal imbalance pathways.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 7 | 566,000 | 392,000 | 2 | 208 | |
| Research and development | 26 | 37 | 29 | 25 | 47 | |
| General and administrative | 24 | 26 | 31 | 32 | 37 | |
| Total operating expenses | 50 | 62 | 60 | 57 | 84 | |
| Loss from operations | −42 | −62 | −59 | −56 | 124 | |
| Other income (expense), net | 25 | 35 | 7 | 1 | −45,690 | |
| Loss before provision for income taxes | −17 | −26 | −52 | −54 | 124 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 1 | |
| Net loss | −17 | −26 | −52 | −54 | 123 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 26 | 27 | 45 | 188 | |
| Marketable securities | 56 | 27 | 79 | 84 | 0 | |
| Prepaid expenses and other current assets | 5 | 3 | 4 | 2 | 3 | |
| Total current assets | 74 | 56 | 110 | 131 | 190 | |
| Marketable securities - noncurrent | 21 | 0 | — | — | — | |
| Long-term equity investments | 42 | 21 | — | — | — | |
| Restricted cash | 2 | 2 | 2 | 2 | 2 | |
| Right-of-use asset, net | 12 | 13 | 14 | 15 | 0 | |
| Property and equipment, net | 252,000 | 433,000 | 769,000 | 1 | 242,757 | |
| Other assets | 0 | 92,000 | 210,000 | 261,191 | 260,126 | |
| Total assets | 151 | 92 | 144 | 155 | 195 | |
| Accounts payable | 2 | 3 | 4 | 2 | 7 | |
| Accrued expenses | 5 | 6 | 7 | 5 | 8 | |
| Current portion, lease liability | 1 | 1 | 1 | 533,946 | 0 | |
| Total current liabilities | 8 | 11 | 11 | 7 | 15 | |
| Lease liability | 12 | 13 | 15 | 16 | 0 | |
| Total liabilities | 20 | 24 | 56 | 23 | 15 | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 0 and 1,250 shares issued and outstanding at December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 1 | 1 | |
| Common stock, $0.001 par value; 315,000,000 and 125,000,000 shares authorized; 130,184,353 and 71,009,866 shares issued and outstanding at December 31, 2025 and 2024, respectively | 130,000 | 71,000 | 71,000 | 70,467 | 70,359 | |
| Additional paid-in-capital | 452 | 372 | 366 | 358 | 351 | |
| Accumulated other comprehensive loss | −202,000 | −35,000 | 1,000 | −42,187 | 0 | |
| Accumulated deficit | −322 | −304 | −278 | −226 | −171 | |
| Total stockholders equity | 131 | 68 | 88 | 132 | 180 | |
| Total liabilities and stockholders equity | 151 | 92 | 144 | 155 | 195 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Change in fair value of royalty monetization liability | 0 | −30 | 0 | — | — | |
| Unrealized gain on equity investments | −21 | −3 | −2 | 454,811 | 0 | |
| Change in accrued interest and accretion of discount on marketable securities | −695,000 | −3 | −2 | −1 | — | |
| Stock-based compensation expense | 5 | 6 | 7 | 7 | 5 | |
| Depreciation and amortization expense | 273,000 | 613,000 | 568,000 | 512,505 | 237,079 | |
| Noncash operating lease expense | 1 | 1 | 1 | 869,100 | 0 | |
| Change in lease liability | −1 | −1 | −534,000 | 936,927 | — | |
| Prepaid expenses and other current assets | −2 | 899,000 | −1 | 109,292 | 40,503 | |
| Accounts payable | −1 | −512,000 | 2 | −5 | 2 | |
| Accrued expenses | −1 | −537,000 | 2 | −3 | −4 | |
| Net cash used in operating activities | −38 | −56 | −46 | −55 | 119 | |
| Purchase of marketable securities | −92 | −73 | −112 | −173 | 0 | |
| Sales/maturities of marketable securities | 42 | 128 | 120 | 90 | 0 | |
| Purchases of property and equipment | 0 | −71,000 | −40,000 | −1 | −184,008 | |
| Software development and other costs | 0 | −90,000 | −97,000 | −194,397 | −5,400 | |
| Net cash (used in) provided by investing activities | −50 | 55 | −3 | −88 | −2 | |
| Proceeds from private placement financing, net of transaction costs | 75 | 0 | — | — | — | |
| Proceeds from exercise of options and employee stock purchase plan | 91,000 | 622,000 | 535,000 | 180,658 | 925,396 | |
| Net cash provided by financing activities | 75 | 622,000 | 31 | 180,658 | 904,082 | |
| Effect of exchange rates on cash, cash equivalents and restricted cash | −167,000 | 0 | — | — | — | |
| Net decrease in cash, cash equivalents and restricted cash | −13 | −740,000 | — | −143 | 118 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Ovid Therapeutics Inc.'s CIK number?
Ovid Therapeutics Inc.'s SEC CIK number is 0001636651 (1636651). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Ovid Therapeutics Inc.'s SEC filings?
All of Ovid Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Ovid Therapeutics Inc. last report earnings?
Ovid Therapeutics Inc. (OVID) most recently filed an earnings 8-K with the SEC on Mar 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-019045). This is Ovid Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Ovid Therapeutics Inc.'s most recent earnings 8-K?
Ovid Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 18, 2026 under accession 0001628280-26-019045. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Ovid Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →